Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:AYTU

Aytu BioPharma - AYTU Stock Forecast, Price & News

$0.19
0.00 (-0.58%)
(As of 11/25/2022 08:57 PM ET)
Add
Compare
Today's Range
$0.18
$0.19
50-Day Range
$0.15
$0.23
52-Week Range
$0.15
$2.40
Volume
1.15 million shs
Average Volume
903,074 shs
Market Capitalization
$11.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.50

Aytu BioPharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,800.8% Upside
$5.50 Price Target
Short Interest
Healthy
2.85% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.22) to $0.01 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

Medical Sector

365th out of 1,044 stocks

Pharmaceutical Preparations Industry

171st out of 510 stocks

AYTU stock logo

About Aytu BioPharma (NASDAQ:AYTU) Stock

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

Receive AYTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter.

AYTU Stock News Headlines

Aytu BioPharma First Quarter 2023 Earnings: Beats Expectations
Aytu BioPharma's Earnings: A Preview
Aytu BioPharma, Inc. (AYTU)
Aytu Biopharma Inc
See More Headlines
Receive AYTU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aytu BioPharma and its competitors with MarketBeat's FREE daily newsletter.

AYTU Company Calendar

Last Earnings
9/27/2022
Today
11/27/2022
Next Earnings (Estimated)
2/13/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AYTU
Fax
N/A
Employees
175
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.50
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+2,800.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-110,170,000.00
Pretax Margin
-83.19%

Debt

Sales & Book Value

Annual Sales
$96.67 million
Cash Flow
$0.90 per share
Book Value
$0.86 per share

Miscellaneous

Free Float
60,585,000
Market Cap
$11.84 million
Optionable
Not Optionable
Beta
-0.21

Key Executives

  • Mr. Joshua R. Disbrow (Age 47)
    Chairman & CEO
    Comp: $567.31k
  • Mr. Mark K. Oki CPA (Age 53)
    CFO, Sec. & Treasurer
    Comp: $217.6k
  • Mr. Jarrett T. Disbrow Ph.D. (Age 47)
    Exec. VP of Corp. Operations
  • Mr. Greg Pyszczymuka
    Chief Commercial Officer
  • Mr. Topher Brooke
    Exec. VP of Rare Disease Devel.
  • Mr. Russ McMahen
    Sr. VP of R&D













AYTU Stock - Frequently Asked Questions

Should I buy or sell Aytu BioPharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aytu BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AYTU shares.
View AYTU analyst ratings
or view top-rated stocks.

What is Aytu BioPharma's stock price forecast for 2023?

1 analysts have issued 1 year price objectives for Aytu BioPharma's stock. Their AYTU share price forecasts range from $5.00 to $6.00. On average, they predict the company's share price to reach $5.50 in the next year. This suggests a possible upside of 2,800.8% from the stock's current price.
View analysts price targets for AYTU
or view top-rated stocks among Wall Street analysts.

How have AYTU shares performed in 2022?

Aytu BioPharma's stock was trading at $1.35 at the start of the year. Since then, AYTU stock has decreased by 86.0% and is now trading at $0.1896.
View the best growth stocks for 2022 here
.

When is Aytu BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our AYTU earnings forecast
.

How were Aytu BioPharma's earnings last quarter?

Aytu BioPharma, Inc. (NASDAQ:AYTU) issued its quarterly earnings data on Tuesday, September, 27th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.01. The business had revenue of $27.45 million for the quarter, compared to the consensus estimate of $25.70 million. Aytu BioPharma had a negative net margin of 83.18% and a negative trailing twelve-month return on equity of 47.20%.

When did Aytu BioPharma's stock split?

Aytu BioPharma's stock reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aytu BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioPharma investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), iBio (IBIO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and SCYNEXIS (SCYX).

What is Aytu BioPharma's stock symbol?

Aytu BioPharma trades on the NASDAQ under the ticker symbol "AYTU."

Who are Aytu BioPharma's major shareholders?

Aytu BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.80%), Vanguard Group Inc. (1.56%), Commonwealth Equity Services LLC (0.34%) and Prudential Financial Inc. (0.23%). Insiders that own company stock include Armistice Capital Master Fund, Armistice Capital, Llc and Joshua R Disbrow.
View institutional ownership trends
.

How do I buy shares of Aytu BioPharma?

Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aytu BioPharma's stock price today?

One share of AYTU stock can currently be purchased for approximately $0.19.

How much money does Aytu BioPharma make?

Aytu BioPharma (NASDAQ:AYTU) has a market capitalization of $11.84 million and generates $96.67 million in revenue each year. The company earns $-110,170,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis.

How many employees does Aytu BioPharma have?

The company employs 175 workers across the globe.

How can I contact Aytu BioPharma?

Aytu BioPharma's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The official website for the company is aytubio.com. The company can be reached via phone at (720) 437-6580 or via email at james@haydenir.com.

This page (NASDAQ:AYTU) was last updated on 11/28/2022 by MarketBeat.com Staff